EMA Authorised: NeoRecormon (epoetin beta) — Roche Registration GmbH

View source ↗

Summary

NeoRecormon (epoetin beta) has been authorised by the EMA for related indications in chronic kidney failure, anemia, cancer, and autologous blood transfusion se…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Blood Transfusion Autologous
• Cancer
• Chronic Kidney Disease

Drugs mentioned

• NeoRecormon (epoetin beta)

Snippet

Status: Authorised. Therapeutic area: Kidney Failure, Chronic;Anemia;Cancer;Blood Transfusion, Autologous. MAH: Roche Registration GmbH. Decision date: 01/05/2025